EcoDrugPlus

Potassium Voltage-Gated Channel, Shal-Related Subfamily, Member 3

Ensembl ID : ENSIPUG00000004845
Gene Symbol: KCND3
3 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2a

Ensembl ID : ENSIPUG00000019793
Gene Symbol: KCNH2A
2 Cross references
156 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2b

Ensembl ID : ENSIPUG00000024833
Gene Symbol: KCNH2B
3 Cross references
185 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSIPUG00000009094
Gene Symbol: PSEN1
4 Cross references
200 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSIPUG00000006840
Gene Symbol: PSEN2
4 Cross references
205 Possible Orthologues:

Progesterone Receptor-Like

Ensembl ID : ENSIPUG00000003898
Gene Symbol: LOC108264046
3 Cross references
193 Possible Orthologues:

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSIPUG00000007708
Gene Symbol: PTGER1B
4 Cross references
164 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSIPUG00000004854
Gene Symbol: PTGER2A
4 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 2b (Subtype Ep2)

Ensembl ID : ENSIPUG00000017963
Gene Symbol: PTGER2B
4 Cross references
170 Possible Orthologues:

Prostaglandin E Receptor 3 (Subtype Ep3)

Ensembl ID : ENSIPUG00000022578
Gene Symbol: PTGER3
3 Cross references
195 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) A

Ensembl ID : ENSIPUG00000025050
Gene Symbol: PTGER4A
4 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor (Fp)

Ensembl ID : ENSIPUG00000012920
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).